Map dopamine signals for mood
- Trial ID
- NCT07402928
- Official Title
- Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease
- Goal
- Map dopamine signals for mood
- Status
- RECRUITING
- Sponsor
- Danish Research Centre for Magnetic Resonance
- Study Type
- OBSERVATIONAL
- Enrollment
- 140 participants
- Conditions
- Healthy, Parkinson, Medication Administration
Plain-Language Summary
Goal: map and model how the brain's dopamine signals code "optimistic" versus "pessimistic" prediction errors during decision making, and compare those signals in people with Parkinson's to healthy adults. Approach: participants perform behavioral tasks while undergoing advanced magnetic resonance scans that track brain activity tied to dopamine-related signals, then researchers use computational models to separate optimistic from pessimistic responses; people with Parkinson's remain on their usual antiparkinsonian medication so the team sees patterns in the typical medicated state. Eligibility: adults 35 and older, either healthy volunteers or people with clinically established or probable akinetic-rigid Parkinson's who are on stable antiparkinsonian meds, not using advanced device therapies, and without MR contraindications, severe depression, or regular antipsychotic or GABAergic medication.
Locations
- Danish Research Centre for Magnetic Resonance (DRCMR), Hvidovre Hospital, Hvidovre, Denmark
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. Goal: map and model how the brain's dopamine signals code "optimistic" versus "pessimistic" prediction errors during decision making, and compare those signals in people with Parkinson's to healthy adults. Approach: participants perform behavioral tasks while undergoing advanced magnetic resonance scans that track brain activity tied to dopamine-related signals, then researchers use computational models to separate optimistic from pessimistic responses; people with Parkinson's remain on their usual antiparkinsonian medication so the team sees patterns in the typical medicated state. Eligibility: adults 35 and older, either healthy volunteers or people with clinically established or probable akinetic-rigid Parkinson's who are on stable antiparkinsonian meds, not using advanced device therapies, and without MR contraindications, severe depression, or regular antipsychotic or GABAergic medication.
- Who can participate?
- Participants must be at least 35 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 1 month.